{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:22:58Z","timestamp":1787710978633,"version":"build-2784847793"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Patients receiving extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome are at high risk of invasive pulmonary aspergillosis, but isavuconazole population pharmacokinetics and target attainment during ECMO remain incompletely characterized. To characterize isavuconazole population pharmacokinetics during ECMO, quantify between-patient variability and the probability of target attainment (PTA) and derive dosing implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Fifteen critically ill adults receiving ECMO and intravenous isavuconazole were studied prospectively, with 148 plasma concentrations measured over 168\u2005h. First loading doses of 200, 300 or 400\u2005mg reflected a stepwise change in institutional practice and were followed in all patients by 200\u2005mg q8h\u200a\u00d7\u200a5 and 200\u2005mg q24h. Individual parameters were estimated by Bayesian forecasting against a literature-informed prior, and PTA was evaluated by simulating 5000 virtual subjects under five maintenance regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Loading-phase exposure increased with the first dose (median AUC0\u201324 14.2, 26.1 and 33.5\u2005mg\u00b7h\/L; P = 0.025) and converged at steady-state. Median Bayesian apparent clearance was 4.06 L\/h, comparable with non-ECMO ICU populations, but between-patient variability was substantially wider (coefficient of variation 116% versus 38%; range 0.77\u201315.73 L\/h). AUC0\u2013\u03c4 \u200a\u2265\u200a60\u2005mg\u00b7h\/L was attained in four of seven patients with an evaluable steady-state profile, and simulation projected 41% attainment under standard maintenance. No regimen achieved &amp;gt;80% efficacy and &amp;gt;80% safety PTA simultaneously. Eight patients (53%) died.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ECMO did not alter isavuconazole population clearance, so routine dose escalation is not warranted. Wide between-patient variability precludes any fixed regimen and favours therapeutic drug monitoring-guided individualized dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag184","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:15:53Z","timestamp":1786706153000},"source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics, target attainment and individualized dosing of isavuconazole in critically ill adults receiving extracorporeal membrane oxygenation"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-0512","authenticated-orcid":false,"given":"Stefan","family":"Hatzl","sequence":"first","affiliation":[{"name":"Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz ,","place":["Austria"]},{"name":"BioTechMed-Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1977-2196","authenticated-orcid":false,"given":"Lisa","family":"Kriegl","sequence":"additional","affiliation":[{"name":"BioTechMed-Graz , Graz ,","place":["Austria"]},{"name":"Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Auenbruggerplatz 15, Graz A-8036 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4918-1749","authenticated-orcid":false,"given":"Christina","family":"Geiger","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Auenbruggerplatz 15, Graz A-8036 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-3646","authenticated-orcid":false,"given":"Philipp","family":"Eller","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6656-3648","authenticated-orcid":false,"given":"Robert","family":"Krause","sequence":"additional","affiliation":[{"name":"BioTechMed-Graz , Graz ,","place":["Austria"]},{"name":"Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Auenbruggerplatz 15, Graz A-8036 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"2026082522012725400_dlag184-B1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026082522012725400_dlag184-B2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s00134-024-07341-7","article-title":"Invasive fungal diseases in adult patients in intensive care unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM","volume":"50","author":"Bassetti","year":"2024","journal-title":"Intensive Care Med"},{"key":"2026082522012725400_dlag184-B3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/cid\/ciae633","article-title":"Performance of diagnostic algorithms in patients with invasive pulmonary aspergillosis","volume":"80","author":"Hatzl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026082522012725400_dlag184-B4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S2213-2600(20)30328-3","article-title":"Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study","volume":"8","author":"Schmidt","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026082522012725400_dlag184-B5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026082522012725400_dlag184-B6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2026082522012725400_dlag184-B7","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1093\/jac\/dkad328","article-title":"Early attainment of isavuconazole target concentration using an increased loading dose in critically ill patients with extracorporeal membrane oxygenation","volume":"78","author":"Hatzl","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026082522012725400_dlag184-B8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12879-025-10627-w","article-title":"Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: a meta-analysis with trial sequential analysis","volume":"25","author":"Weng","year":"2025","journal-title":"BMC Infect Dis"},{"key":"2026082522012725400_dlag184-B9","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001437","article-title":"Extracorporeal membrane oxygenation can affect posaconazole exposure in critically ill patients","author":"Chai","year":"2026","journal-title":"Ther Drug Monit"},{"key":"2026082522012725400_dlag184-B10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/jac\/dkp026","article-title":"Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"63","author":"Spriet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2026082522012725400_dlag184-B11","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00134-007-0606-2","article-title":"Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment","volume":"33","author":"Mehta","year":"2007","journal-title":"Intensive Care Med"},{"key":"2026082522012725400_dlag184-B12","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082522012725400_dlag184-B13","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40262-023-01305-8","article-title":"Population pharmacokinetics of total and unbound isavuconazole in critically ill patients: implications for adaptive dosing strategies","volume":"62","author":"Jansen","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026082522012725400_dlag184-B14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/17425255.2025.2545920","article-title":"Suboptimal concentrations of isavuconazole in critically ill patients treated for mold infections: a population pharmacokinetic analysis","volume":"21","author":"Rabault","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026082522012725400_dlag184-B15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026082522012725400_dlag184-B16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/jof6020090","article-title":"Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations","volume":"6","author":"Zurl","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026082522012725400_dlag184-B17","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1093\/jac\/dkac196","article-title":"Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation","volume":"77","author":"Kriegl","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026082522012725400_dlag184-B18","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/jac\/dkw098","article-title":"Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints","volume":"71","author":"Kovanda","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026082522012725400_dlag184-B19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"2026082522012725400_dlag184-B20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082522012725400_dlag184-B21","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026082522012725400_dlag184-B22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"H\u00f6hl","year":"2022","journal-title":"Mycoses"},{"key":"2026082522012725400_dlag184-B23","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaf507","article-title":"Empirical antifungal treatment of critically ill patients with influenza-associated acute respiratory distress syndrome: a propensity score weighted observational study","volume":"82","author":"Hatzl","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026082522012725400_dlag184-B24","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1093\/jac\/dkw111","article-title":"Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection","volume":"71","author":"Barchiesi","year":"2016","journal-title":"J Antimicrob Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag184\/70775618\/dlag184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag184\/70775618\/dlag184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:01:33Z","timestamp":1787709693000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag184\/8769933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag184","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dlag184"}}